Investor Presentaiton slide image

Investor Presentaiton

MediMobility Organ Transport Overview Largest dedicated air transporter of human organs for transplant, providing end-to-end multi-modal solution incorporating rotorcraft, fixed- wing aircraft, and ground vehicles Medical missions utilize the same aircraft that service passenger flights, with demand typically occurring at night, complementing consumer demand during the day and providing more hours for aircraft operators to amortize their fixed costs Fixed pricing model per trip enables predictable flight profit and allows for fuel cost pass-through Organ transport represents a clear use case for future drone or EVA adoption, particularly given necessary infrastructure and landing zones are already in place at many hospitals Key Value Proposition Attractive, Growing End Market Non-cyclical, B2B revenue with limited marketing and strong end market growth MediMobility Organ Transport Trailing Twelve Month Revenues ($ in mm) $116 $103 $86 $72 $60 $42 Improves Patient $26 CIT TRANSPLANT Shorter transport time results in improved organ quality and higher success rates $15 $3 $4 $5 $6 Outcomes Air M Low-Cost Provider Vast operator network provides customers appropriate aircraft for each mission with competitive pricing Complements Consumer Business Fleet commonality increases utilization of aircraft otherwise idle at night Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Organ Transplants in the US(1) Heart, Liver, and Lung ~43K Organs Transplanted in 2022 Kidney & Other Note: Definition of all non-GAAP numbers and reconciliation to GAAP numbers are provided in the Appendix of this presentation 1. Source: United Network for Organ Sharing (UNOS) Data and Transplant Statistics. Blade primarily services the Heart, Liver, and Lung segment of the organ logistics market BLADE 19
View entire presentation